FDA-APPROVED CHIKUNGUNYA VACCINE. SCOTTSDALE, AZ

Chikungunya Vaccine in Arizona

Chikungunya has spread to more than 110 countries across the Caribbean, Latin America, Africa, South Asia, and Southeast Asia. A single dose of the FDA-approved VIMKUNYA vaccine offers strong protection before you travel. Expert consultations and same-day appointments often available at our Scottsdale travel clinic.

Call (480) 435-2774 Book Online

~99% seroconversion . 1 dose . 28 days to protection

QUICK FACTS

Chikungunya is a viral disease transmitted by mosquitoes, known for causing severe joint pain and fever. It can lead to long-term health issues and requires prompt medical attention.

  • Outbreaks have occurred in countries in Africa, The Americas, Asia, Europe, and the Caribbean, Indian and Pacific Oceans.
  • There is a risk the virus will be spread to unaffected areas by infected travelers. There is currently no medicine to treat chikungunya virus infection.
  • Only one Chikungunya vaccine is currently licensed in the United States. It is administered as a single dose.

Chikungunya: Debilitating Joint Pain With No Cure

Chikungunya is a viral illness transmitted by the bite of infected Aedes aegypti and Aedes albopictus mosquitoes. First identified in Tanzania in 1952, its name comes from the Makonde language and means “that which bends up,” a reference to the stooped posture caused by severe joint pain. What began as a regional disease has become a global concern, now circulating in more than 110 countries across the Caribbean, Central and South America, Africa, South Asia, Southeast Asia, and parts of the Pacific.

There is no specific antiviral treatment for chikungunya. Care is limited to managing symptoms with rest, fluids, and pain relievers. The acute phase typically lasts one to two weeks, but the disease can be particularly cruel in its aftermath. Studies estimate that 30 to 40 percent of those infected develop chronic arthralgia, with joint pain and swelling persisting for months or, in some cases, years after the initial infection. Chikungunya is rarely fatal, but it is one of the most physically disabling mosquito-borne illnesses a traveler can contract.

The FDA-approved chikungunya vaccine currently available in the United States is VIMKUNYA, developed by Bavarian Nordic. VIMKUNYA is a single-dose virus-like particle (VLP) vaccine. It is not a live vaccine. The virus-like particle is a protein shell that mimics the chikungunya virus to the immune system without containing any viral genetic material, so it cannot replicate or cause infection. FDA approval was issued in February 2025 for individuals ages 12 and older. Clinical trials demonstrated a strong neutralizing antibody response in the great majority of recipients within weeks of vaccination.

Who Should Consider the Chikungunya Vaccine

The CDC recommends chikungunya vaccination for travelers ages 12 and older who are at increased risk of exposure. Talk with our travel medicine team if any of the following apply to your trip:

  • You are traveling to the Caribbean, Central America, South America, Sub-Saharan Africa, South Asia, or Southeast Asia
  • Your destination has reported active chikungunya transmission in the past year
  • You will spend significant time outdoors during daylight hours, when Aedes mosquitoes are most active
  • You are staying in open-air accommodations, rural areas, or areas with limited air conditioning
  • You are an older adult or have joint conditions that would make prolonged arthralgia especially burdensome
  • You are a long-term expatriate, volunteer, missionary, researcher, or frequent traveler to endemic regions

Medically Reviewed By

Norman J. Bizon, PA-C, CTH® is Medical Director at TravelBug Health. Over 30 years of clinical experience and certified in travel medicine and international health.

Tessa E. McFall, ASN, EMT is a Travel Health Specialist Clinician at TravelBug Health.

Last updated April 21, 2026

DESTINATIONS

Where Chikungunya Is a Risk

Chikungunya circulates in tropical and subtropical regions across more than 110 countries. Transmission intensity fluctuates with seasonal rainfall, local mosquito populations, and ongoing outbreak cycles. Always confirm current conditions at your consultation.

Caribbean Islands. Chikungunya was first introduced to the Americas via the Caribbean in late 2013. The Dominican Republic, Haiti, Jamaica, Trinidad and Tobago, Puerto Rico, Barbados, St. Lucia, Martinique, Guadeloupe, and most other island nations have documented ongoing or intermittent transmission. Risk is present year-round.

Mexico. Documented transmission in Pacific and Gulf coast states, the Yucatan Peninsula, and parts of southern Mexico. Popular beach destinations including Cancun, Los Cabos, Puerto Vallarta, and Playa del Carmen all carry seasonal risk. If your travel is limited to Mexico City, high-altitude inland regions, or northern border cities, the risk is lower.

Central America. Guatemala, Honduras, El Salvador, Nicaragua, Costa Rica, and Panama all have documented chikungunya transmission. Travelers on adventure itineraries, those staying outside hotels with air conditioning, and long-stay visitors face the highest exposure.

Brazil. Brazil has experienced large and sustained chikungunya outbreaks, with hundreds of thousands of cases reported annually. All major regions carry risk, including coastal cities. Travelers visiting Rio de Janeiro, Salvador, and the northeast are at particular risk during and after rainy season.

Colombia. Established endemic transmission throughout the country, particularly in the Caribbean and Pacific coastal regions and in lowland areas. Bogota, at high altitude, carries lower risk. Most other destinations warrant vaccine consideration.

Venezuela, Ecuador, Peru, Bolivia. Transmission has been documented in lowland tropical areas. Ecuador’s coast and Amazon region carry risk. High-altitude destinations such as Quito and Cusco are lower risk. Confirm your specific itinerary at your appointment.

East Africa. Kenya, Tanzania, Uganda, Ethiopia, and Mozambique have all reported chikungunya cases. Tanzania was the site of the original 1952 outbreak identification. Travelers on safari, humanitarian missions, or extended stays in East Africa should discuss vaccination.

West Africa. Nigeria, Senegal, Cote d’Ivoire, Ghana, and neighboring countries have documented periodic outbreaks. Risk is endemic across the region and tends to intensify during rainy seasons when mosquito populations are highest.

Central Africa. The Democratic Republic of Congo, Cameroon, Central African Republic, and other central African nations have reported chikungunya transmission. Travelers to these destinations for any extended period should consider vaccination.

Reunion Island and Indian Ocean Islands. Reunion experienced the largest documented chikungunya outbreak in history in 2005 to 2006, affecting an estimated one-third of the island’s population. Comoros, Mayotte, Madagascar, and Seychelles have all reported transmission as well.

Southern Africa. South Africa, Zambia, Zimbabwe, and surrounding nations have had sporadic reports. Risk is lower than in East or West Africa but not absent. Discuss your specific destination and activities at your consultation.

Sudan and Horn of Africa. Sudan, Somalia, and Djibouti have documented cases and outbreaks. Travelers to this region for humanitarian, research, or occupational purposes should evaluate vaccination based on exposure duration and activities.

India. India bears among the world’s largest chikungunya burdens, with millions of cases reported since the 2005 to 2006 epidemic that swept through southern and central India. Transmission is present in most states. Major cities including Delhi, Mumbai, Chennai, and Bengaluru all have documented urban transmission.

Sri Lanka. Chikungunya is endemic in Sri Lanka, with outbreaks recurring across the island. Travelers visiting for tourism, cultural immersion, or volunteer work face real exposure risk, particularly outside of major hotels.

Thailand. Active transmission documented throughout the country, including tourist destinations in the south and around Bangkok. Both urban and rural itineraries carry risk. Thailand is a destination where many travelers underestimate mosquito-borne illness exposure.

Indonesia, Malaysia, Philippines. All three countries have sustained and recurring chikungunya transmission. Popular destinations including Bali, Lombok, Cebu, and Palawan are not exempt. Travelers spending time in local communities, resorts with open-air layouts, or rural areas face elevated exposure.

Myanmar, Laos, Cambodia, Vietnam. Documented transmission across mainland Southeast Asia. Travelers on overland itineraries, volunteer programs, or extended cultural stays should consider vaccination regardless of which specific countries are on the itinerary.

Pacific Islands. Fiji, Samoa, Tonga, Papua New Guinea, New Caledonia, and other Pacific island nations have experienced outbreaks. Aedes albopictus mosquitoes are established across much of the Pacific, creating ongoing outbreak potential. Confirm current transmission status at your appointment.

SAFETY

Who Should Not Get the Chikungunya Vaccine

VIMKUNYA is a non-live, virus-like particle vaccine. It is appropriate for most travelers ages 12 and older, including many patients in whom older live-virus travel vaccines would have been off the table. A short list of situations still calls for caution. We review your history at your consultation and make the call together.

Contraindications

You should not receive VIMKUNYA, or should receive it only after careful consultation, if you:

  • Are under 12 years of age (FDA approval covers ages 12 and older)
  • Have a history of severe allergic reaction (including anaphylaxis) to any component of the vaccine or a prior dose
  • Are pregnant or breastfeeding — data are limited; risk and benefit are reviewed individually based on destination risk
  • Have an acute moderate or severe illness — defer until recovery

If a Contraindication Applies

If the vaccine is not appropriate for you, the focus shifts to aggressive mosquito bite prevention – DEET or picaridin containing repellents, permethrin-treated clothing and gear, long sleeves and pants during peak daytime mosquito hours, and accommodations with air conditioning or window screens.

We counsel every patient on these protective measures regardless of vaccination status. For patients whose medical complexity makes vaccination inadvisable, we document the clinical rationale and coordinate recommendations with your prescribing physician if needed.

Call to Discuss Your Case

SPECIAL CONSIDERATIONS

Specific Situations We Handle

Travelers With Arthritis or Joint Disease

Chikungunya can trigger prolonged, severe arthralgia that may persist for months. For travelers who already live with rheumatoid arthritis, osteoarthritis, or other joint conditions, a chikungunya infection could significantly worsen baseline function. Vaccination is often strongly advisable in this group, pending a review of immunosuppressant medications.

Biologics and Immunosuppressants

VIMKUNYA is a non-live, virus-like particle vaccine, so the absolute contraindications that apply to live travel vaccines do not apply here. Patients on Humira, Enbrel, Remicade, Rituxan, Xeljanz, and similar agents can generally be vaccinated, though immune response may be reduced. Bring a complete medication list and we will coordinate with your prescribing physician where appropriate.

Pregnancy

VIMKUNYA is non-live, but human data in pregnancy remain limited. The decision is individualized: destination risk, trimester, and whether travel can be deferred all factor in. If travel to an endemic region is unavoidable, aggressive mosquito bite prevention is the primary strategy. We also counsel patients on the risk that chikungunya infection itself poses during pregnancy, including the possibility of vertical transmission to the newborn.

Adults 60 and Older

Older travelers are often the ones who would suffer most from chronic post-chikungunya joint pain. Because VIMKUNYA is not a live vaccine, the live-virus age cautions that applied to earlier chikungunya products do not apply here. We still walk through your overall medical picture and any underlying joint or autoimmune conditions before vaccinating.

Travelers Under 12

VIMKUNYA is FDA-approved for ages 12 and older. Children under 12 traveling to endemic regions are not currently eligible for chikungunya vaccination. We provide detailed mosquito bite prevention counseling for families, including age-appropriate repellent use and protective clothing strategies.

Long-Term Travelers and Expatriates

Cumulative exposure time is a key driver of chikungunya risk. Travelers spending weeks or months in endemic regions face substantially higher lifetime exposure than short-stay tourists. Educators, missionaries, NGO workers, researchers, and corporate expatriates assigned to endemic regions should strongly consider vaccination before departure.

Post-Travel Illness Guidance

If you return from an endemic region with fever and severe joint pain, seek evaluation promptly. Chikungunya, dengue, and Zika can present similarly. A travel history and targeted lab work help distinguish them. 

EFFECTIVENESS

Strong Protection From a Single Dose.

VIMKUNYA was evaluated in pivotal clinical trials in adolescents and adults. The great majority of recipients developed neutralizing antibodies against chikungunya virus within weeks of a single dose, with strong seroresponse across age groups, including older adults.

Because chikungunya outbreaks are geographically unpredictable and sporadic, a traditional field-efficacy trial was not feasible on the timeline needed for vaccine development. The immunogenicity data is the regulatory basis for FDA approval, consistent with how several other vaccines for rare or outbreak-driven pathogens have been evaluated.

Antibody durability data through six months of follow-up showed sustained protective levels. Longer-term immunogenicity and potential booster need are actively under study. Current guidance does not call for a booster dose.

~99%

Seroconversion
Protective antibodies at 28 days

1

Dose
For ages 12 and older

28 days to protection

Vaccinate at least 4 weeks before departure to your destination

COST AND INSURANCE

What to Expect at Checkout

Travel vaccines are generally not covered by commercial health insurance, Medicare, or Medicaid because they are considered elective rather than medically necessary. That pattern is industry-wide.

At Your Appointment

You’ll be charged for:

  • Travel health consultation (itinerary-based risk assessment)
  • The chikungunya vaccine itself
  • Any other vaccines or prescriptions you elect

Pricing varies based on services. Call (480) 435-2774 for current pricing. We are transparent so there are no surprises.

What to Ask Your Insurer

Before your appointment, call the member services number on your insurance card and ask:

  • Does my plan cover travel vaccines, including chikungunya?
  • What CPT code do I submit for the chikungunya vaccine? (Confirm the current code with our office before your appointment, plus an office-visit code)
  • Do I need pre-authorization?
  • Can I apply HSA or FSA funds?

For Reimbursement

After your appointment, we provide a detailed itemized receipt with:

  • CPT codes
  • Diagnosis codes
  • Clinician’s NPI
  • Itemized line items

Reimbursement outcome is between you and your insurer.

SAFETY PROFILE

Side Effects and Safety

VIMKUNYA was evaluated in pivotal clinical trials in adolescents and adults. As a non-live, virus-like particle vaccine, its reactogenicity profile is consistent with other modern adjuvanted or recombinant vaccines: mostly mild, short-lived injection-site and systemic symptoms.

COMMON. MORE THAN 10%

Mild and Self-Limited

  • Injection-site pain, tenderness, redness, or swelling
  • Headache
  • Fatigue
  • Muscle aches
  • Low-grade fever

Most symptoms appear within the first few days after vaccination and resolve on their own within 1 to 3 days.

UNCOMMON

Other Systemic Reactions

A smaller proportion of recipients report joint pain, nausea, or chills in the days following vaccination. Because VIMKUNYA is non-live, these are immune responses to the vaccine antigen, not a viral infection. They typically resolve on their own within a few days.

In clinical trials, serious adverse events attributable to the vaccine were uncommon. Your provider will review your individual risk factors before administering.

RARE. SEEK IMMEDIATE CARE

Severe Allergic Reaction

Anaphylaxis is a rare but possible reaction to any injectable vaccine. Signs include hives, throat tightening, difficulty breathing, or dizziness, typically appearing within 15 to 30 minutes of vaccination. We observe all vaccinated patients for 15 minutes after injection.

If you have a history of severe allergic reactions to vaccines or their components, bring documentation and discuss it with our team before your appointment.

A note on post-vaccination symptoms: VIMKUNYA does not contain live virus and cannot cause chikungunya infection. Any short-lived joint or muscle soreness after vaccination is an immune response, not disease. If symptoms are severe, persist beyond 10 to 14 days, or concern you, contact us or your primary care provider.

WHAT HAPPENS NEXT

After Your Chikungunya Vaccination

1

Allow 28 Days

Full protective immunity develops over approximately 28 days. Plan to get vaccinated at least four weeks before departure, ideally sooner so we can coordinate any other vaccines or travel medications your itinerary requires.

2

Expect Mild Symptoms

Headache, fatigue, joint aches, or a low-grade fever in the first seven days are common and expected. Rest, stay hydrated, and use acetaminophen for comfort. Call us if symptoms are severe, involve a rash or difficulty breathing, or persist past 14 days.

3

Maintain Mosquito Protection

The vaccine significantly reduces your risk, but no vaccine eliminates it entirely. Use DEET or picaridin containing repellent during outdoor activities, wear long sleeves and pants in the morning and late afternoon when Aedes mosquitoes are most active, and choose air-conditioned accommodations when available.

4

Coordinate Other Vaccines

The chikungunya vaccine can be given the same day as inactivated vaccines. If you also need live vaccines such as MMR or oral typhoid, we coordinate the timing at your consultation to ensure proper spacing and immune response for each.

WHY A TRAVEL CLINIC

TravelBug vs. Primary Care or Pharmacy

VIMKUNYA is a newer specialty travel vaccine that primary care offices and retail pharmacies usuallydo not carry. Here is how a dedicated travel clinic differs from the alternatives.

TravelBug Health

  • Chikungunya vaccine (VIMKUNYA) in stock
  • Specialist-led itinerary-based risk consultation
  • Same-day or next-day appointments often available
  • Coordinates full panel of travel vaccines
  • Comprehensive mosquito-borne illness counseling
  •  

PCP or Retail Pharmacy

  • Often does not stock VIMKUNYA
  • Limited or general consultation only
  • Variable scheduling
  • Limited stock of travel-specific vaccines
  • brief or no mosquito-borne illness prevention counseling

SCHEDULE YOUR VACCINATION

TravelBug Health in Scottsdale

We are a dedicated travel medicine clinic in the heart of the Phoenix metro. We carry the FDA-approved chikungunya vaccine and see travelers from across the Valley and northern Arizona. We have the flexible scheduling and travel-medicine specialization that primary-care offices and retail pharmacies cannot match.

TravelBug Health Travel Clinic
8603 E Royal Palm Rd, Suite 120
Scottsdale, AZ 85258

Phone: (480) 435-2774
Email: team@travelbughealth.com
Hours: Monday to Friday, 9:00 AM to 5:00 PM (by appointment)

Call Now Book Online

Just minutes from across the Valley

North Scottsdale near the 101 and Shea Blvd:

No referral required. Same-day and next-day appointments are often available. Call us with your itinerary and we’ll find a time.

QUESTIONS TRAVELERS ASK

Frequently Asked Questions

The FDA-approved chikungunya vaccine currently available in the United States is VIMKUNYA, manufactured by Bavarian Nordic. It received FDA approval in February 2025 for individuals ages 12 and older. VIMKUNYA is a single-dose virus-like particle (VLP) vaccine. It is not a live vaccine — the virus-like particle is a protein shell that triggers an immune response without containing any viral genetic material.

Pricing varies based on your specific consultation and services rendered. Call (480) 435-2774 for current pricing before your appointment. We are transparent about costs so there are no surprises. Travel vaccines are typically not covered by commercial insurance, Medicare, or Medicaid, though we provide itemized receipts for HSA, FSA, or partial-reimbursement claims.

Most commercial health insurance plans, Medicare, and Medicaid do not cover travel vaccines, including chikungunya. Some plans may offer partial reimbursement if you submit a claim with the appropriate CPT and diagnosis codes. HSA and FSA funds can generally be applied. We provide all required documentation after your visit.

In clinical trials, approximately 98 to 99 percent of participants developed neutralizing antibodies associated with protection against chikungunya virus at 28 days after vaccination. Because chikungunya outbreaks are geographically unpredictable, the vaccine was approved based on this immunogenicity data, consistent with regulatory precedent for outbreak-driven pathogens.

Yes, vaccination is generally recommended. The Caribbean has had sustained chikungunya transmission since the virus was first introduced to the region in late 2013. Popular destinations including the Dominican Republic, Jamaica, Haiti, Puerto Rico, Trinidad and Tobago, Barbados, and the French Antilles all carry ongoing risk. The vaccine is not required for entry, but it offers meaningful protection against a debilitating illness.

Vaccination is worth considering for most Mexican destinations, particularly coastal and tropical areas. Chikungunya transmission has been documented in the Yucatan Peninsula, Pacific coast states, Gulf coast, and southern Mexico, including popular tourist areas. If your travel is limited to Mexico City, high-altitude inland regions, or northern border cities, the risk is lower. Discuss your specific itinerary with our team.

Chikungunya is rarely fatal in healthy adults, but it is one of the most debilitating mosquito-borne illnesses a traveler can contract. The acute phase involves high fever and severe joint pain that can be incapacitating for days to weeks. More concerning for many patients is the chronic arthralgia that affects an estimated 30 to 40 percent of those infected, with joint pain and swelling persisting for months or years after the initial illness. Older adults and those with pre-existing joint conditions tend to fare worse.

Chikungunya is spread exclusively through the bites of infected Aedes aegypti and Aedes albopictus mosquitoes. It is not spread person to person. Unlike malaria-transmitting mosquitoes, which are most active at dusk and dawn, Aedes mosquitoes bite primarily during daylight hours, including mid-morning and late afternoon. This means standard mosquito nets used at night do not provide complete protection.

Both are transmitted by Aedes mosquitoes and cause fever, but they differ in important ways. Chikungunya’s hallmark is severe joint pain that can persist for months after the acute illness. Dengue more commonly causes intense bone and muscle pain, rash, and in severe cases, bleeding or plasma leakage. A blood test can distinguish them, which matters because management differs. Both can circulate in the same geographic areas at the same time.

VIMKUNYA is not a live vaccine, but human pregnancy data remain limited. The decision is individualized based on destination risk, trimester, and whether travel can be deferred. If travel to an endemic region is unavoidable, strict mosquito bite prevention is the primary strategy. We also counsel patients on the risk that chikungunya infection itself poses during pregnancy, including the possibility of vertical transmission to the newborn. Postponing or adjusting the trip is often the preferred approach when possible.

Adolescents 12 and older are eligible. VIMKUNYA is FDA-approved for ages 12 and up. Children under 12 are not currently eligible; pediatric studies in younger age groups are ongoing. For children under 12 traveling to endemic regions, the prevention strategy centers on insect repellents appropriate for the child’s age, permethrin-treated clothing and gear, and protective clothing during peak daytime mosquito activity hours.

No. VIMKUNYA is a virus-like particle (VLP) vaccine. The virus-like particle is a protein shell that mimics the chikungunya virus to the immune system but contains no viral genetic material, so it cannot replicate or cause infection. Because it is non-live, the contraindications that apply to live travel vaccines (such as immunocompromise) do not apply the same way here.

At least four weeks before departure, so that full protective immunity can develop before you arrive at your destination. Plan even earlier if you also need other travel vaccines or medications, so we can coordinate everything without rushing. Call us as soon as your travel is confirmed.

VIMKUNYA is a specialty travel vaccine that many retail pharmacies and most primary care offices do not carry. TravelBug Health stocks it and can administer it alongside a full travel medicine consultation. Call (480) 435-2774 to confirm availability and schedule your appointment.

The most common side effects of VIMKUNYA are injection-site pain or tenderness, headache, fatigue, muscle aches, and low-grade fever. Most are mild and self-limited, appearing in the first few days after vaccination and resolving on their own within 1 to 3 days. VIMKUNYA is non-live and cannot cause chikungunya infection. Serious adverse events were uncommon in clinical trials. Anaphylaxis, while rare, is possible with any injectable vaccine, which is why we observe patients for 15 minutes after administration.

Current guidance does not call for a booster dose. A single dose produced sustained protective antibody levels through six months of follow-up in clinical trials. Longer-term durability studies are ongoing. We will stay current with ACIP and CDC guidance and update our recommendations accordingly.

  • A detailed travel itinerary (destinations, dates, planned activities)
  • Prior immunization records, if available
  • A current medication list, especially any biologics, immunosuppressants, or cancer therapies
  • Documentation of any prior severe allergic reactions to vaccines or medications

Generally yes. Because VIMKUNYA is a non-live virus-like particle vaccine, it does not carry the same scheduling constraints as live travel vaccines. It can typically be co-administered with other vaccines you may need for your trip, including hepatitis A, hepatitis B, typhoid, and others. We coordinate the full panel at your consultation and recommend scheduling as early as possible before departure.

Ready to Travel Protected?

Schedule Your Chikungunya Vaccination

No referral required. Same-day and next-day appointments often available. We handle the consultation, the vaccine, and all the documentation in one visit.

Call (480) 435-2774 Book Online